Federal action targets some synthetic opioids linked to kratom

The supplied news coverage describes a changing legal landscape for products sold as related to kratom. It says some products have been sold in vape shops, convenience stores and online, including in Michigan and other states.

The report distinguishes natural kratom leaf from more concentrated or fully lab-made products. Kratom is a plant that grows in South Asia. It naturally contains small amounts of 7-hydroxymitragynine, known as 7-OH. The article says products sold as concentrated 7-OH, rather than natural kratom leaf, contain lab-made 7-OH at much higher concentrations than the plant leaf.

It also discusses three compounds described as entirely lab-made: mitragynine pseudoindoxyl, MGM-15 and MGM-16. According to the coverage, the DEA temporarily placed these three substances in Schedule I as of Aug. 26, 2026. Schedule I is the federal category that includes substances such as heroin and LSD. The article says this status would make selling or prescribing those compounds illegal across the United States.

The report says 7-OH itself was not yet federally scheduled as of that date. It describes a reopened public-comment period on a proposed temporary Schedule I action for 7-OH products above a certain threshold. But the excerpt does not state what that threshold is. It says the comment period runs through Sept. 10 and that the DEA could decide afterward whether to move forward.

The coverage says the DEA proposed these actions in response to reported increases in poisonings, addiction cases and overdose deaths since synthetic opioid products entered the U.S. market in late 2024. However, the supplied excerpt does not include the underlying surveillance data, numbers of cases or deaths, definitions of those outcomes, or a comparison showing how much of the increase may be tied to these products. It therefore cannot show how common these harms are or prove that wider product availability caused them.

The article also says that kratom, 7-OH and related compounds act on opioid receptors in the brain. Opioid receptors are parts of brain cells involved in the effects of opioid drugs. It describes some people developing cravings or needing higher amounts for the same effect. But the excerpt provides no estimates of how often this occurs, who may be most affected, or how risks differ among natural leaf kratom, concentrated 7-OH and the fully synthetic compounds.

Natural kratom leaf products are described as outside the federal actions discussed in the excerpt. Still, the report notes that some states, counties and cities have separately banned or regulated kratom, 7-OH or synthetic opioids. Local rules may therefore differ from federal policy.

Despite the original headline’s reference to addiction care, the supplied text does not explain what care is available, how people can find it, or which approaches have been studied for people using these products. The excerpt also ends mid-sentence, so it may leave out relevant policy details. More complete regulatory documents and evidence on harms and care would be needed for a fuller picture.